ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRVA vs MRK // REVENUE GROWTH (YOY)

Privia Health Group Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PRVA 2 — MRK 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRVA VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRVA MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 10.50% 20.70% -10.20 MRK /roic <GO>
EV/EBITDA & P/E Valuation 68.1x 15.3x +52.80 MRK /valuation <GO>
Free Cash Flow Yield 5.82% 3.42% +2.40 PRVA /fcf-yield <GO>
Operating Margin — 34.30% — TIE /operating-margins <GO>
Net Profit Margin — 28.10% — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.0 51.7 +3.30 PRVA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 114.0x 18.4x +95.60 MRK /forward-pe <GO>
Enterprise Scale & Market Cap $2.81B $361.02B -$358.21B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRVA REV MRK REV PRVA GROSS % MRK GROSS % PRVA FCF MRK FCF
FY 2025 $0 $65.01B — 74.8% $163.4M $12.36B
FY 2024 $0 $64.17B — 76.3% $109.3M $18.10B
FY 2023 $0 $60.12B — — $80.8M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRVA // BETA —
MRK // BETA 0.92